|
[Related PubMed/MEDLINE]
Total Number of Papers: 228
|
|
|
| |
|
[Display Entries]
|
|
>> all entries
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
| Page: of |
|
|
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2020 |
Aggressive B-cell lymphomas with a primary bone marrow presentation. |
BL, BM, HG-BCLs, TdT |
| 2 |
2020 |
Conditional expression of HGAL leads to the development of diffuse large B-cell lymphoma in mice. |
BCR, GC, HSC |
| 3 |
2020 |
Hepatitis B virus-associated B-cell non-Hodgkin lymphoma in non-endemic areas in Western Europe: Clinical characteristics and prognosis. |
HBV, NHL |
| 4 |
2020 |
Microsatellite instability and its associations with the clinicopathologic characteristics of diffuse large B-cell lymphoma. |
CR, MSI, OS, PFS |
| 5 |
2020 |
Primary large B-cell lymphoma of the central nervous system with cyclin D1 expression and t(11;14) (IGH-CCND1): Diffuse large B-cell lymphoma with CCND1 rearrangement or mantle cell lymphoma? |
CCND1, CNS, MCLs |
| 6 |
2020 |
RNAscope dual ISH-IHC technology to study angiogenesis in diffuse large B-cell lymphomas. |
JAK, STAT |
| 7 |
2020 |
Single-cell analysis of germinal-center B cells informs on lymphoma cell of origin and outcome. |
COO, GCs, sc |
| 8 |
2020 |
TET2 deficiency reprograms the germinal center B cell epigenome and silences genes linked to lymphomagenesis. |
GC |
| 9 |
2020 |
TET2 deficiency reprograms the germinal center B cell epigenome and silences genes linked to lymphomagenesis. |
GC |
| 10 |
2020 |
Tumor lysis syndrome as a risk factor for very early mortality in HIV-associated non-Hodgkin's lymphoma: A 10-year single-center experience. |
BLs, NHL, PCNSLs, PLWHIV, TLS |
| 11 |
2020 |
Visible and near-infrared hyperspectral imaging techniques allow the reliable quantification of prognostic markers in lymphomas: A pilot study using the Ki67 proliferation index as an example. |
DIA, FLs, HSI, VA, Vis-NIR |
| 12 |
2019 |
Array-based profiling of the lymphoma cell DNA methylome does not unequivocally distinguish primary lymphomas of the central nervous system from non-CNS diffuse large B-cell lymphomas. |
CNS, PCNSL |
| 13 |
2019 |
Characteristics of CD5-positive diffuse large B-cell lymphoma among Koreans: High incidence of BCL2 and MYC double-expressors. |
--- |
| 14 |
2019 |
Chromatin remodeling factor lymphoid-specific helicase links with Epstein-Barr virus associated the follicular germinal center B cell lymphomas. |
5hmC, BLs, EBV, LSH |
| 15 |
2019 |
Clinicopathological characteristics of diffuse large B-cell lymphoma involving small and large intestines: an analysis of 126 patients. |
FL, MALT |
| 16 |
2019 |
Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas. |
DAAs, DLBCL, HCV, ICT, R-CHOP, SeqC |
| 17 |
2019 |
Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2. |
BCR, BRD4, DEL, DHL |
| 18 |
2019 |
EBV microRNA-BHRF1-2-5p targets the 3'UTR of immune checkpoint ligands PD-L1 and PD-L2. |
3'UTR, ABCs, BHRF1, COO, GCBs, LMP1, miR, PD-L1 |
| 19 |
2019 |
GATA3 Immunohistochemical Staining in Hodgkin Lymphoma: Diagnostic Utility in Differentiating Classic Hodgkin Lymphoma From Nodular Lymphocyte Predominant Hodgkin Lymphoma and Other Mimicking Entities. |
cHL, EBV, NLPHL, NS, PMBLs, TCHRBCLs |
| 20 |
2019 |
Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network. |
CI, CSF, DC, LYSA, PCNSLs, R/R |
| 21 |
2019 |
Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA). |
CR, LOC, LYSA, non-GCB, ORR, OS, PCNSLs, PFS, PR, PVRL, R/R |
| 22 |
2019 |
Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†. |
CR, LOC, LYSA, non-GCB, ORR, OS, PCNSLs, PFS, PR, PVRL, R/R |
| 23 |
2019 |
LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL. |
DSB, HR, PARP, T-ALL |
| 24 |
2019 |
Methotrexate-associated Lymphoproliferative Disorders in Patients With Rheumatoid Arthritis: Clinicopathologic Features and Prognostic Factors. |
cHL, LPDs, MTX, MTX-LPDs, Poly-LPD, RH |
| 25 |
2019 |
NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019. |
FL, PI3K, TFL |
| 26 |
2019 |
Non-oncogene Addiction to SIRT3 Plays a Critical Role in Lymphomagenesis. |
GC |
| 27 |
2019 |
Physical torment: A predisposition for diffuse B-cell lymphoma. |
NHLs |
| 28 |
2019 |
Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium. |
Ig, MYC-R |
| 29 |
2019 |
Prohibitin (PHB) expression is associated with aggressiveness in DLBCL and flavagline-mediated inhibition of cytoplasmic PHB functions induces anti-tumor effects. |
ABC, EFS, GCB, IHC, PHB, PHB1, PHB2 |
| 30 |
2019 |
The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH. |
FISH, GCB-DLBCLs |
| 31 |
2019 |
Tumour necrosis as assessed with 18F-FDG PET is a potential prognostic marker in diffuse large B cell lymphoma independent of MYC rearrangements. |
DSS, MATV, TLG |
| 32 |
2018 |
Activated CARD11 accelerates germinal center kinetics, promoting mTORC1 and terminal differentiation. |
aCARD11, GC |
| 33 |
2018 |
De Novo Unclassifiable CD20-Negative Diffuse Large B-Cell Lymphoma: A Diagnostic and Therapeutic Challenge. |
EBV, HHV-8, HIV |
| 34 |
2018 |
Discovery of an Irreversible and Cell-Active BCL6 Inhibitor Selectively Targeting Cys53 Located at the Protein-Protein Interaction Interface. |
BCL6, PPI |
| 35 |
2018 |
Double hit and double expressors in lymphoma: Definition and treatment. |
Bcl-2, BCL6, DEL, DHL |
| 36 |
2018 |
Efficacy and safety of new direct antiviral agents in hepatitis C virus-infected patients with diffuse large B-cell non-Hodgkin's lymphoma. |
AVT, DAAs, DFS, HCV, IPI, NHL, OS |
| 37 |
2018 |
Epstein-Barr virus infection in B-cell Non-Hodgkin's Lymphomas of the oral and maxillofacial region: Is there any evidence? |
BLs, EBV, NHLs |
| 38 |
2018 |
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. |
ABC, GCB |
| 39 |
2018 |
Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type. |
DLBCL-LT, DLBCL-NOS, NFKBIE or REL |
| 40 |
2018 |
How Biophysical Forces Regulate Human B Cell Lymphomas. |
BCRs |
| 41 |
2018 |
PCR-based clonality analysis of antigen receptor gene rearrangements in canine cutaneous plasmacytoma. |
CD3, FR, IgH, MUM1 |
| 42 |
2018 |
Primary extranodal diffuse large B-cell lymphomas: Many sites, many entities? Clinico-pathological, immunohistochemical and cytogenetic study of 106 cases. |
DES, EN, FISH |
| 43 |
2018 |
Some diffuse large B cell lymphomas (DLBCLs) present with clone-dependent TTF-1 positivity. |
--- |
| 44 |
2018 |
[Diagnostic and therapeutic values of interphase fluorescence in situ hybridization in B-cell lymphomas: a clinicopathologic analysis of 604 cases]. |
FISH, GCB, LBL |
| 45 |
2017 |
A new diagnostic marker for differentiating multicentric gliomas from multiple intracranial diffuse large B-cell lymphomas on 18F-FDG PET images. |
F-FDG, MRI, PET, ROC, T/N |
| 46 |
2017 |
A novel in vivo model for studying conditional dual loss of BLIMP-1 and p53 in B-cells, leading to tumor transformation. |
ABC, Blimp-1 |
| 47 |
2017 |
Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements. |
FISH, HGBLs |
| 48 |
2017 |
CD30 Expression in Monomorphic Posttransplant Lymphoproliferative Disorder, Diffuse Large B-Cell Lymphoma Correlates With Greater Regulatory T-Cell Infiltration. |
PTLDs |
| 49 |
2017 |
Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm. |
ABC, GCB, R-CHOP |
| 50 |
2017 |
Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis. |
ABC, GCB |
| 51 |
2017 |
Differential contribution of the mitochondrial translation pathway to the survival of diffuse large B-cell lymphoma subsets. |
BCR, ETC |
| 52 |
2017 |
DNMT1 is predictive of survival and associated with Ki-67 expression in R-CHOP-treated diffuse large B-cell lymphomas. |
GCB, OS, PFS |
| 53 |
2017 |
Expressions of the CagA protein and CagA-signaling molecules predict Helicobacter pylori dependence of early-stage gastric DLBCL. |
CagA, HP, p-ERK, p-SHP2 |
| 54 |
2017 |
Germline mutations predisposing to diffuse large B-cell lymphoma. |
--- |
| 55 |
2017 |
Hematologic Malignancies Discovered on Investigation of Breast Abnormalities. |
FLs, MZLs |
| 56 |
2017 |
LMO2-negative Expression Predicts the Presence of MYC Translocations in Aggressive B-Cell Lymphomas. |
BL, LBCL |
| 57 |
2017 |
MYC Immunohistochemistry Predicts MYC Rearrangements by FISH. |
BL, FISH, IHC |
| 58 |
2017 |
Primary Soft Tissue Lymphomas: Description of Seven Cases and Review of the Literature. |
--- |
| 59 |
2017 |
Tumor Microenvironment and Checkpoint Molecules in Primary Cutaneous Diffuse Large B-Cell Lymphoma-New Therapeutic Targets. |
CD68, LT, MDSCs, OT, pcDLBCL, PD-L1 |
| 60 |
2016 |
An analysis of MYC and EBV in diffuse large B-cell lymphomas associated with angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma not otherwise specified. |
AITL, EBV, HRS-L, PTCLs |
| 61 |
2016 |
An oxidative stress-based mechanism of doxorubicin cytotoxicity suggests new therapeutic strategies in ABC-DLBCL. |
ABC, DOX, GCB |
| 62 |
2016 |
CD20-negative diffuse large B cell lymphoma: a comprehensive analysis of 695 cases. |
--- |
| 63 |
2016 |
Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas. |
mRNA |
| 64 |
2016 |
Epigenetic gene regulation by Janus kinase 1 in diffuse large B-cell lymphoma. |
ABC, JAKs |
| 65 |
2016 |
Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas. |
cHL, PD-1, PDL1 |
| 66 |
2016 |
FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas. |
BCR, FOXO1, Syk |
| 67 |
2016 |
FOXO1 is a TXN- and p300-dependent sensor and effector of oxidative stress in diffuse large B-cell lymphomas characterized by increased oxidative metabolism. |
ROS |
| 68 |
2016 |
Functional Implications of the spectrum of BCL2 mutations in Lymphoma. |
FLD |
| 69 |
2016 |
Long Non-coding RNA HOTAIR Expression in Diffuse Large B-Cell Lymphoma: In Relation to Polycomb Repressive Complex Pathway Proteins and H3K27 Trimethylation. |
HOTAIR, PRC2 |
| 70 |
2016 |
miR-10a inhibits cell proliferation and promotes cell apoptosis by targeting BCL6 in diffuse large B-cell lymphoma. |
3'-UTR, BCL6 |
| 71 |
2016 |
PATZ1 expression correlates positively with BAX and negatively with BCL6 and survival in human diffuse large B cell lymphomas. |
GCB, NHLs |
| 72 |
2016 |
Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma. |
ABC-DLBCLs, BCL6 |
| 73 |
2016 |
Targetable subsets of non-Hodgkin lymphoma in Malawi define therapeutic opportunities. |
GCB, IHC, LMICs, LST, NHL |
| 74 |
2016 |
UCH-L1 in DLBCL: marker or target? |
ABC-DLBCL, GC, UCH-L1 |
| 75 |
2015 |
CD43 expression in diffuse large B-cell lymphoma, not otherwise specified: CD43 is a marker of adverse prognosis. |
DLBCL-NOS |
| 76 |
2015 |
Loss of PRDM11 promotes MYC-driven lymphomagenesis. |
PRDM |
| 77 |
2015 |
MLL/KMT2A translocations in diffuse large B-cell lymphomas. |
--- |
| 78 |
2015 |
MYC in DLBCL: partners matter. |
MYC-Rs |
| 79 |
2015 |
Overexpression of Activation-Induced Cytidine Deaminase in MTX- and Age-Related Epstein-Barr Virus-Associated B-Cell Lymphoproliferative Disorders of the Head and Neck. |
AID, EBV, Egr-1, LMP1, LPDs |
| 80 |
2015 |
The expanding spectrum of EBV+ lymphomas. |
--- |
| 81 |
2015 |
The histological classification of diffuse large B-cell lymphomas. |
--- |
| 82 |
2014 |
AIDS-related non-Hodgkin lymphoma: imaging feature analysis of 27 cases and correlation with pathologic findings. |
HAART, NHL, PCNS |
| 83 |
2014 |
An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. |
OS, PFS, R-CHOP, TAMs |
| 84 |
2014 |
Clinical, morphologic, phenotypic, and genetic evidence of cyclin D1-positive diffuse large B-cell lymphomas with CYCLIN D1 gene rearrangements. |
MCL |
| 85 |
2014 |
Diffuse large B-cell lymphoma of the sinonasal tract: analysis of survival in 852 cases. |
DSS, SEER |
| 86 |
2014 |
Exome sequencing reveals novel mutation targets in diffuse large B-cell lymphomas derived from Chinese patients. |
--- |
| 87 |
2014 |
Inhibiting CARD11 translation during BCR activation by targeting the eIF4A RNA helicase. |
BCR, Ig, UTR |
| 88 |
2014 |
Pellino 1 promotes lymphomagenesis by deregulating BCL6 polyubiquitination. |
PELI1, TCR |
| 89 |
2014 |
Primary diffuse large B-cell lymphoma in the anterior hard palate: A rare case report with review of literature. |
NHL |
| 90 |
2014 |
Relevance of miR-21 in HIV and non-HIV-related lymphomas. |
miRNAs, mRNA, UTR, VMP1 |
| 91 |
2014 |
The truncate mutation of Notch2 enhances cell proliferation through activating the NF-kappaB signal pathway in the diffuse large B-cell lymphomas. |
PDTC |
| 92 |
2014 |
Utility and diagnostic pitfalls of SOX11 monoclonal antibodies in mantle cell lymphoma and other lymphoproliferative disorders. |
MCL |
| 93 |
2013 |
A capture-sequencing strategy identifies IRF8, EBF1, and APRIL as novel IGH fusion partners in B-cell lymphoma. |
IgH |
| 94 |
2013 |
A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters. |
GC |
| 95 |
2013 |
Clinical analysis and prognostic significance of hepatitis B virus infections for diffuse large B-cell lymphoma with or without rituximab therapy. |
beta2m, CHOP, HBsAg, HBV, IPI, LDH, OS |
| 96 |
2013 |
Clinical presentation of anaplastic large-cell lymphoma in the central nervous system. |
ALCL, ALK, CNS, HD-MTX, OS |
| 97 |
2013 |
De novo CD5-positive diffuse large B-cell lymphomas show high specificity for cyclin D2 expression. |
--- |
| 98 |
2013 |
DNA repair genes are selectively mutated in diffuse large B cell lymphomas. |
NHEJ |
| 99 |
2013 |
EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. |
ABC, GC, GCB |
| 100 |
2013 |
Frequency and extent of CD30 expression in diffuse large B-cell lymphoma and its relation to clinical and biologic factors: a retrospective study of 167 cases. |
CI, OR |
|
A Search Service for Abbreviation / Long Form
